The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases
ID: RFA-DK-23-017_RFA-DK-23-018Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NICHDBETHESDA, MD, 20817, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

MEDICAL- OTHER (Q999)

Original Source

https://sam.gov/opp/c7b47e26151e40f38804ba34321b7179/view
Timeline
    Description

    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking industry partners for clinical research collaborations focused on therapeutics, diagnostics, or devices for childhood cholestatic liver diseases. The initiative aims to engage collaborators in providing novel therapeutic agents and diagnostic tools for use in NIH-sponsored multi-center clinical trials targeting conditions such as biliary atresia and alpha-one antitrypsin deficiency, among others. This collaboration is critical for advancing research and improving clinical outcomes for children suffering from these rare liver diseases. Interested organizations must submit a Capability Statement detailing their proposed solutions and capabilities, with no funding provided by NIDDK for this opportunity. For inquiries, contact Edward Doo at dooe@niddk.nih.gov or Katrina Loh at katrina.loh@nih.gov.

    Files
    No associated files provided.
    Similar Opportunities
    The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for the Liver Cirrhosis Network
    Active
    Health And Human Services, Department Of
    Special Notice HEALTH AND HUMAN SERVICES, DEPARTMENT OF seeks industry partners for clinical research collaborations on therapeutics, diagnostics or devices for the Liver Cirrhosis Network. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is looking for industry collaborators to provide novel or repurposed therapeutic agents, diagnostic markers, biomarkers, devices, or services for use in NIH-sponsored multi-center clinical trials and ancillary studies in adult patients with advanced liver disease and cirrhosis. The Liver Cirrhosis Network aims to promote clinical and translational research on cirrhosis of the liver and related complications in adults. The network is interested in conducting research that will lead to improved clinical outcomes in adults with cirrhosis and advanced liver disease. Commercial organizations interested in pursuing clinical collaborations with NIDDK for cirrhosis liver disease are required to submit a Capability Statement to the NIDDK.
    Industry Collaboration for the Kidney Precision Medicine Project (KPMP)
    Active
    Health And Human Services, Department Of
    Special Notice: HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking Industry collaborators for the Kidney Precision Medicine Project (KPMP). This project aims to conduct multi-center clinical and molecular studies in individuals with Diabetic Kidney Disease, Hypertension-related Chronic Kidney Disease, or Acute Kidney Injury. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS) is leading this initiative. Industry collaboration is sought to support the research and development efforts in these areas of kidney diseases.
    NIDDK Scientist
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Child Health and Human Development (NICHD), is seeking to procure the services of a specialized scientist through a non-competitive contract with Optimal Systems, LLC. The objective of this procurement is to leverage the contractor's expertise in biomedical imaging and medical image analysis to develop a non-invasive, cost-effective alternative to liver biopsy for assessing liver inflammation, a critical need for millions affected by liver disease. The contractor will implement a 3D Magnetic Resonance Elastography (MRE) technique, develop algorithms for liver tissue analysis, and utilize machine learning to evaluate inflammation levels, with deliverables including weekly status meetings and contributions to scientific publications. The anticipated contract period is from February 2, 2025, to February 1, 2026, with payment terms set to monthly in arrears. Interested parties may express their interest, but the decision on whether to pursue a competitive process lies solely with the government. For further inquiries, contact Ijada C. Fields at ijada.fields@nih.gov or 301-435-5452.
    Vendor Collaboration - MULTI-CENTER CLINICAL TRIALS OF NOVEL THERAPIES FOR PATIENTS WITH WELL CHARACTERIZED GASTROPARESIS
    Active
    None
    Special Notice: Vendor Collaboration - MULTI-CENTER CLINICAL TRIALS OF NOVEL THERAPIES FOR PATIENTS WITH WELL CHARACTERIZED GASTROPARESIS This federal procurement notice is seeking vendors to collaborate on multi-center clinical trials of novel therapies for patients with well-characterized gastroparesis. Gastroparesis is a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, and abdominal pain. The purpose of this procurement is to find vendors who can contribute to the development and testing of new therapies for gastroparesis patients. The trials will involve multiple centers, allowing for a diverse patient population and a comprehensive evaluation of the effectiveness of the therapies. Vendors interested in this opportunity should refer to the uploaded document for collaboration details. For further information, please contact the primary contracting officer, Richard Bailey, at BaileyRichard@mail.nih.gov or 301-402-1139, or the secondary contracting officer, Marlene T. Mireles, at mirelesm@mail.nih.gov or 301-443-7795. By successfully fulfilling this procurement, you will not only contribute to the advancement of medical research but also make a positive impact on the lives of patients suffering from gastroparesis.
    In Vitro Assessments of Antimicrobial Activity
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity program to support in vitro testing for evaluating the therapeutic potential of compounds against infectious diseases. This initiative aims to enhance the understanding and treatment of infectious diseases by providing efficient assessment tools integrated into the product development pipeline, focusing on various pathogens including bacteria, fungi, viruses, and challenging pathogens that require innovative culturing techniques. The RFP will be available online around December 30, 2024, and proposals must be submitted via the NIAID electronic Contract Proposal Submission (eCPS) platform; interested parties can contact Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov for further information.
    iNDI ALFAtag cell lines for the iPSC Neurodegenetive Disease Initiative (iNDI) project
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small businesses to provide iNDI ALFAtag cell lines for the iPSC Neurodegenerative Disease Initiative (iNDI) project. The primary objective of this procurement is to generate a collection of up to 230 genetically engineered isogenic cell lines related to Alzheimer's disease and related dementias, which will serve as a national cell repository for the scientific community. These cell lines will be utilized to characterize how genetic mutations affect disease-relevant cell types, with specific requirements for quality control and genetic validation processes. Interested vendors must submit their capability statements by December 27, 2024, at 12:00 PM Eastern Time, to Andrea Clay at amcgee@mail.nih.gov, and should include their company details and relevant qualifications.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    The Role of Mitochondrial Genetic Variation in Dementia
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified small business sources for a project titled "The Role of Mitochondrial Genetic Variation in Dementia." The objective of this procurement is to obtain laboratory analysis of mitochondrial genetic variation in brain tissue samples from dementia patients, which will aid in understanding the relationship between mitochondrial function and Alzheimer's disease. This initiative is crucial as it aims to explore potential pathways to dementia through the examination of mitochondrial DNA mutations and oxidative capacity in patient samples. Interested contractors must submit their responses by January 2, 2025, to Kevin Alvarez at kevin.alvarez@nih.gov, detailing their capabilities and business size status, as this opportunity is particularly focused on small businesses.
    Long Sequencing Kits
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) NIDA, is seeking qualified small businesses to provide Long Sequencing Kits as part of a Sources Sought notice. The primary objective of this procurement is to acquire kits that facilitate long read sequencing for analyzing biomarkers related to Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD), which are crucial for understanding disease progression and therapeutic efficacy. The kits must meet specific technical requirements, including compatibility with Nanopore PromethION 48 sequencers and the ability to generate substantial sequencing data in real-time. Interested parties must submit their capability statements to Andrea Clay at amcgee@nida.nih.gov by December 31, 2024, at 12:00 PM Eastern Time, as this notice is strictly for research and information purposes and does not obligate the government to award a contract.
    2026 NIAID DMID Omnibus Broad Agency Announcement
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and specifically the National Institute of Allergy and Infectious Diseases (NIAID), is soliciting proposals for the 2026 DMID Omnibus Broad Agency Announcement (BAA) aimed at advancing research and development of medical countermeasures against antimicrobial-resistant pathogens and viruses with pandemic potential. The BAA encompasses two primary research areas: the development of therapeutics, vaccines, and diagnostics for antimicrobial-resistant bacterial and fungal pathogens, and the creation of direct-acting antivirals for viral families of pandemic potential. This initiative is critical for addressing public health challenges related to infectious diseases and enhancing biodefense capabilities. Proposals for Research Area 001 are due by February 21, 2025, while those for Research Area 002 are due by January 21, 2025. Interested parties can reach out to primary contact Swee L. Teo at teosl@niaid.nih.gov or 240-669-5173 for further information.